Condition
Primary Antiphospholipid Syndrome
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 3 (1)
Trial Status
Unknown2
Recruiting1
Completed1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05904301Recruiting
Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases
NCT06504420Phase 2Not Yet RecruitingPrimary
The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study
NCT03459508CompletedPrimary
Ocular Findings in Women With Primary Antiphospholipid Syndrome
NCT03540810Phase 3UnknownPrimary
Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome
NCT01956188Not ApplicableUnknown
Omega 3 in LES and APS
Showing all 5 trials